

Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington's Disease by SEN0014196 (PADDINGTON)

<https://www.neurodegenerationresearch.eu/survey/pharmacodynamic-approaches-to-demonstration-of-disease-modification-in-huntingtons-disease-by-sen0014196-paddington/>

Title of project or programme

Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington's Disease by SEN0014196 (PADDINGTON)

Principal Investigators of project/programme grant

Title	Forname	Surname	Institution	Country
Dr	Giovanna	Tripepi	Siena Biotech Spa	Italy

Address of institution of lead PI

Institution Siena Biotech Spa

Street Address

City

Postcode

Country

Italy

Source of funding information

European Commission

Total sum awarded (Euro)

5816314

Start date of award

01-07-2010

Total duration of award in months

36

The project/programme is most relevant to

- Huntington's disease

Keywords

Research abstract in English

The Consortium will undertake clinical research activities aimed at ascertaining feasibility of a range of pharmacodynamic readouts for use in the clinical development of SEN0014196 to demonstrate the disease-modifying properties of the compound in Huntington's Disease. SEN0014196 is a novel and selective SirT1 inhibitor, currently in Phase I clinical development, and enjoys Orphan Status in the EU as of September 2, 2009. A multi-factorial approach will be used, including assessment of both novel and compound-specific measures of molecular action as well as previously identified predictors of disease progression. The translational approaches addressed by this project are instrumental in the progression of SEN0014196 to clinical proof-of-concept and, if successful, will play a pivotal role in patient stratification and outcomes research. The Consortium will comprise four partners, all with a proven track-record in Research and Development in the Huntington's Disease area. All Partners are based within the EU

Lay summary